Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct. 21, 2026 /PRNewswire/ -- Geneos Therapeutics, a...
Scage Future Provides Business Update on Deliveries, Technology Portfolio and Growth Initiatives; Initiates Regular Investor Communication
NANJING, China, Oct. 12, 2026 /PRNewswire/ -- Scage Future (Nasdaq: SCAG) ("Scage" or the "Company"), a provider of new energy and zero-emission heavy-duty commercial vehicles and e-fuel solutions, today provided an update on its commercial...
Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data
First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration subcutaneous formulation designed to combine BBT001's emerging profile of rapid, deep and durable...
Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 Million
– LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD Anderson Cancer Center – – Jie D'Elia, Ph.D., joins as Chief Executive Officer and Friedrich Graf...
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...
Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...
Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC
WUXI, China, Sept. 2, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regulatory clearance from China's National Medical...
Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide. U.S. IRB Approval for Pivotal Phase 3 Trial SUPREME-01 (CBL-0301)—The...
SuperX Announces Progress on Share Repurchase Program, Initiates New Buyback Plan to Reinforce Confidence in Long-Term Growth Value
SINGAPORE, Aug. 7, 2026 /PRNewswire/ -- SuperX AI Technology Limited (Nasdaq: SUPX, the "Company" or "SuperX"), a provider of AI infrastructure solutions, today announced an update on the progress of its share repurchase program and the adoption of...
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature...